BABalamurali Krishna Ambati

Balamurali Krishna Ambati

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Balamurali Krishna Ambati has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • Hironori Uehara

    Moran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT 84132, USA

    11 shared publications
  • Bonnie Archer

    Phil and Penny Knight for Accelerating Scientific Impact, University of Oregon, Eugene, OR

    8 shared publications
  • Subrata Kumar Das

    School of Biomedical Engineering and Health Sciences, Shobhit Institute of Engineering and Technology, NH 58, Meerut 250110, India

    6 shared publications
  • Xiaohui Zhang

    Ambati Lab, John A. Moran Eye Center, Salt Lake City, UT, USA; Department of Ophthalmology & Visual Sciences, University of Utah, Salt Lake City, UT, USA

    5 shared publications
  • Brian C. Stagg

    Moran Eye Center, University of Utah, Salt Lake City, Utah, USA

    4 shared publications
  • Xiaohui Zhang

    Dept. of Ophthalmology, Moran Eye Center, University of Utah, 65 Mario Capecchi Dr., Salt Lake City, UT, 84132, United States

    4 shared publications

Latest Publications

  • Brillouin Optical Spectroscopy for In Vivo and Ex Vivo Assessment of Corneal Biomechanics

    by Sangeetha Ravi Kumar, Kaitlyn Hunter, Baila Shakaib, Patricia Garcia, Bonnie Archer, Casey Check, Cameron Mulder, Balamurali K. Ambati

    Purpose: Corneal ectasias, such as keratoconus, exhibit altered corneal shape, structure, and biomechanics. Patients would greatly benefit from volumetric, 3-dimensional, and regional measurements of corneal stiffness for early detection and post-treatment monitoring. Current methods use indirect measurements, confounded by intraocular pressure, corneal thickness, describing a global picture of the cornea, and fail to identify crucial early localized changes. We tested the Brillouin Optical Scanner System (BOSS), which uses the Brillouin principle for noncontact focal measurement of compressibility and corneal stiffness, expressed as the 3-dimensional Brillouin Longitudinal Modulus. Methods: We measured compressibility/corneal stiffness in 3-month and 10-month-old New Zealand white rabbits (n = 2; male = 1; female = 1). Rabbits remained awake, calm, and nonsedated. We separately analyzed ex vivo porcine corneas using BOSS (n = 28) and strip extensiometry (n = 13). The BOSS parameters were optimized for both sets of analyses. Results: The BOSS demonstrated precise measurements in in vivo rabbits and ex vivo porcine corneas with a <2% and <4% variation from the mean. All rabbit corneas (n = 4) showed an increase in Brillouin values, demonstrating an increase in corneal stiffness over 7 months, in vivo. Conclusions: The BOSS is capable of precise measurements and detecting subtle changes in corneal stiffness in the rabbits. The high precision and accuracy of biomechanical measurements in nonsedated rabbits will enable a reduction in preclinical animal numbers, especially for time course studies. Importantly, the ability of the BOSS to provide spatial biomechanical measurements makes it a valuable tool for early detection of asymmetric corneal ectasias and keratoconus.

  • Pediatric keratoconus: a review of the literature

    by Sabrina Mukhtar, Balamurali K. Ambati

    Purpose To describe the epidemiology and prevalence, rates of progression, difference between adult and pediatric populations, and therapeutic approaches to pediatric keratoconus from documented literature. Methods A literature search was done on PubMed using key words including pediatric keratoconus, children with keratoconus, adult keratoconus, penetrating keratoplasty, corneal cross-linking and intracorneal ring segments. The literature was reviewed and reported to explore the key epidemiological differences between the pediatric and adult population with regards to presentation and treatment options. Results Pediatric keratoconus is more aggressive than adult keratoconus, which has been explained by structural differences in the cornea between both populations. High rates of progression were documented in pediatric populations. While corneal collagen cross-linking, intracorneal ring segments and penetrating keratoplasties have been used as therapies in the pediatric population, the literature overwhelmingly shows higher rates of failure and progression despite these measures as compared to adults. Conclusion Pediatric keratoconus is more aggressive than adult keratoconus, and current therapies used in adults may not be sufficient for the pediatric population.


  • Open Access

    Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment

    by Xiaohui Zhang, Austin Bohner, Sai Bhuvanagiri, Hironori Uehara, Arun Kumar Upadhyay, Lyska L. Emerson, Sailaja Bondalapati, Santosh Kumar Muddana, Daniel Fang, Miaoling Li, et al.


  • Top Cited Papers

    Risk factors and biomarkers of age-related macular degeneration

    by Nathan G. Lambert, Hanan ElShelmani, Malkit K. Singh, Fiona C. Mansergh, Michael A. Wride, Maximilian Padilla, David Keegan, Ruth E. Hogg, Balamurali K. Ambati


  • Hydrogel ocular sealant for wound closure during intrastromal corneal ring segment implantation

    by Ruju R. Rai, Wyatt B. Messenger, Balamurali K. Ambati

    We present a new technique for the sutureless closure of corneal incisions after intrastromal corneal ring segment (ICRS) insertion. Twelve eyes of 7 patients with keratoconus were treated at our institution by the same surgeon with femtosecond laser-assisted ICRS implantation followed by slit-incision closure with a hydrogel ocular sealant. A retrospective review of clinical characteristics was performed over a mean follow-up of 5 months and compared with previously published data on traditional methods for wound management after ICRS insertion. All visual, refractive, and topographic outcomes were within expected limits. No adverse events were observed. Hydrogel ocular sealant was deemed to be a safe, effective, and surgeon-friendly option for wound closure during ICRS implantation. None of the authors has a financial or proprietary interest in any material or method mentioned.


  • Subretinal AAV2.COMP-Ang1 suppresses choroidal neovascularization and vascular endothelial growth factor in a murine model of age-related macular degeneration

    by Nathan G. Lambert, Xiaohui Zhang, Ruju R. Rai, Hironori Uehara, Susie Choi, Lara S. Carroll, Subrata K. Das, Judd M. Cahoon, Brian H. Kirk, Blaine M. Bentley, et al.


  • Safety of undiluted intracameral moxifloxacin without postoperative topical antibiotics in cataract surgery

    by Andrew Xingyu Zhou, Wyatt Boyer Messenger, Steven Sargent, Balamurali Krishna Ambati

    The objective of this study is to evaluate the safety of undiluted 0.5 % intracameral moxifloxacin for postoperative endophthalmitis prophylaxis in cataract surgery patients without the use of additional postoperative topical antibiotics. All phacoemulsification cataract surgeries performed by a single surgeon (B.A.) at the John A. Moran Eye Center from June 2012 to May 2015 were reviewed retrospectively. From June 2012 to April 2014, patients were given topical 0.5 % moxifloxacin postoperatively. From May 2014 to May 2015, all patients were given moxifloxacin intracamerally with no antibiotics postoperatively. The follow-up period was 1 month after surgery. Preoperative visual acuity and postoperative visual acuity, corneal edema, and anterior chamber reaction were recorded and compared between the two groups. 384 cataract surgeries were performed during the study period. None of the 384 eyes in the study developed endophthalmitis. Of those 384 eyes, 222 were included in the study for analysis based on the inclusion and exclusion criteria. 131 were part of the topical antibiotic group and 91 were part of the intracameral group. The differences in uncorrected visual acuity at 1 day postoperatively (p = 0.595) and best corrected visual acuity at 1 month postoperatively (p = 0.099) were not statistically significant. Differences in corneal edema (p = 0.370) and anterior chamber reaction (p = 0.069) at 1 day postoperatively and corneal edema (p = 0.512) and anterior chamber reaction (p = 0.512) at 1 month postoperatively were also not statistically significant. Undiluted 0.5 % moxifloxacin can be safely injected intracamerally following cataract surgery without additional postoperative antibiotic prophylaxis to prevent endophthalmitis without adverse effects on patient outcomes.


  • Open Access

    Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy

    by Judd M. Cahoon, Ruju R. Rai, Lara S. Carroll, Hironori Uehara, Xiaohui Zhang, Christina L. O’nEil, Reinhold J. Medina, Subtrata K. Das, Santosh K. Muddana, Paul R. Olson, et al.

    Diabetic retinopathy (DR) is the leading cause of blindness in the working-age population in the U.S. The vision-threatening processes of neuroglial and vascular dysfunction in DR occur in concert, driven by hyperglycemia and propelled by a pathway of inflammation, ischemia, vasodegeneration, and breakdown of the blood retinal barrier. Currently, no therapies exist for normalizing the vasculature in DR. Here, we show that a single intravitreal dose of adeno-associated virus serotype 2 encoding a more stable, soluble, and potent form of angiopoietin 1 (AAV2.COMP-Ang1) can ameliorate the structural and functional hallmarks of DR in Ins2Akita mice, with sustained effects observed through six months. In early DR, AAV2.COMP-Ang1 restored leukocyte-endothelial interaction, retinal oxygenation, vascular density, vascular marker expression, vessel permeability, retinal thickness, inner retinal cellularity, and retinal neurophysiological response to levels comparable with nondiabetic controls. In late DR, AAV2.COMP-Ang1 enhanced the therapeutic benefit of intravitreally delivered endothelial colony-forming cells by promoting their integration into the vasculature and thereby stemming further visual decline. AAV2.COMP-Ang1 single-dose gene therapy can prevent neurovascular pathology, support vascular regeneration, and stabilize vision in DR.


  • In vivo ZW800-microbead imaging of retinal and choroidal vascular leakage in mice

    by Isha Gupta, Judd Cahoon, Xiaohui Zhang, Alex D. Jones, Faisal Ahmed, Hironori Uehara, Wyatt Messenger, Balamurali K. Ambati